Stephen F Smagula1, Francis E Lotrich1, Howard J Aizenstein1, Breno S Diniz2, Jeffrey Krystek1, Gregory F Wu3, Benoit H Mulsant4, Meryl A Butters1, Charles F Reynolds1,5, Eric J Lenze6. 1. Department of Psychiatry, Western Psychiatric Institute and Clinic of University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 2. Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX, USA. 3. Department of Neurology, Washington University School of Medicine, St Louis, MO, USA. 4. Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada. 5. Department of Behavioral and Community Health Sciences, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA. 6. Healthy Mind Lab, Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA.
Abstract
OBJECTIVE: Several immunological biomarkers are altered in late-life major depressive disorder (LLD). Immunological alterations could contribute to LLD's consequences, but little is known about the relations between specific immunological biomarkers and brain health in LLD. We performed an exploratory pilot study to identify, from several candidates, the specific immunological biomarkers related to important aspects of brain health that are altered in LLD (brain structure and executive function). METHODS: Adults (n = 31) were at least 60 years old and had major depressive disorder. A multiplex immunoassay assessed 13 immunological biomarkers, and we examined their associations with structural MRI (grey matter volume and white matter hyperintensity volume (WMH)) and executive function (Color-Word Interference and Trail-Making tests) measures. RESULTS: Vascular endothelial growth factor (VEGF) and the chemokine eotaxin had significant negative associations with grey matter volume (VEGF: n = 31, r = -0.65; eotaxin: n = 29, r = -0.44). Tumor necrosis factor alpha (TNF-α) had a significant positive relationship with WMHs (n = 30, r = 0.52); interferon-γ (IFN-γ) and macrophage inflammatory protein-1α (MIP-1α) were also significantly associated with WMHs (IFN-γ: n = 31, r = 0.48; MIP-1α: n = 29, r = 0.45). Only eotaxin was associated with executive function (set-shifting performance as measured with the Trail-making test: n = 33, r = -0.43). CONCLUSIONS: Immunological markers are associated with brain structure in LLD. We found the immunological correlates of grey and white matter differ. Prospective studies are needed to evaluate whether these immunological correlates of brain health increase the risk of LLD's consequences. Eotaxin, which correlated with both grey matter volume and set-shifting performance, may be particularly relevant to neurodegeneration and cognition in LLD.
OBJECTIVE: Several immunological biomarkers are altered in late-life major depressive disorder (LLD). Immunological alterations could contribute to LLD's consequences, but little is known about the relations between specific immunological biomarkers and brain health in LLD. We performed an exploratory pilot study to identify, from several candidates, the specific immunological biomarkers related to important aspects of brain health that are altered in LLD (brain structure and executive function). METHODS: Adults (n = 31) were at least 60 years old and had major depressive disorder. A multiplex immunoassay assessed 13 immunological biomarkers, and we examined their associations with structural MRI (grey matter volume and white matter hyperintensity volume (WMH)) and executive function (Color-Word Interference and Trail-Making tests) measures. RESULTS:Vascular endothelial growth factor (VEGF) and the chemokine eotaxin had significant negative associations with grey matter volume (VEGF: n = 31, r = -0.65; eotaxin: n = 29, r = -0.44). Tumor necrosis factor alpha (TNF-α) had a significant positive relationship with WMHs (n = 30, r = 0.52); interferon-γ (IFN-γ) and macrophage inflammatory protein-1α (MIP-1α) were also significantly associated with WMHs (IFN-γ: n = 31, r = 0.48; MIP-1α: n = 29, r = 0.45). Only eotaxin was associated with executive function (set-shifting performance as measured with the Trail-making test: n = 33, r = -0.43). CONCLUSIONS: Immunological markers are associated with brain structure in LLD. We found the immunological correlates of grey and white matter differ. Prospective studies are needed to evaluate whether these immunological correlates of brain health increase the risk of LLD's consequences. Eotaxin, which correlated with both grey matter volume and set-shifting performance, may be particularly relevant to neurodegeneration and cognition in LLD.
Authors: Harris A Eyre; Tracy Air; Alyssa Pradhan; James Johnston; Helen Lavretsky; Michael J Stuart; Bernhard T Baune Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2016-02-20 Impact factor: 5.067
Authors: Ashkan Shoamanesh; Sarah R Preis; Alexa S Beiser; Ramachandran S Vasan; Emelia J Benjamin; Carlos S Kase; Philip A Wolf; Charles DeCarli; Jose R Romero; Sudha Seshadri Journal: Neurology Date: 2015-01-28 Impact factor: 9.910
Authors: Sarah Shizuko Morimoto; Faith M Gunning; Dora Kanellopoulos; Christopher F Murphy; Sibel A Klimstra; Robert E Kelly; George S Alexopoulos Journal: Int J Geriatr Psychiatry Date: 2011-05-25 Impact factor: 3.485
Authors: N M Simon; K McNamara; C W Chow; R S Maser; G I Papakostas; M H Pollack; A A Nierenberg; M Fava; K K Wong Journal: Eur Neuropsychopharmacol Date: 2007-08-03 Impact factor: 4.600
Authors: Ian Joel; Amy E Begley; Benoit H Mulsant; Eric J Lenze; Sati Mazumdar; Mary Amanda Dew; Daniel Blumberger; Meryl Butters; Charles F Reynolds Journal: Am J Geriatr Psychiatry Date: 2013-02-06 Impact factor: 4.105
Authors: Charles L Raison; Robin E Rutherford; Bobbi J Woolwine; Chen Shuo; Pamela Schettler; Daniel F Drake; Ebrahim Haroon; Andrew H Miller Journal: JAMA Psychiatry Date: 2013-01 Impact factor: 21.596
Authors: Pedro V S Magalhaes; Karen Jansen; Laura Stertz; Pamela Ferrari; Ricardo Tavares Pinheiro; Ricardo A da Silva; Flávio Kapczinski Journal: J Psychiatr Res Date: 2013-10-20 Impact factor: 4.791
Authors: Stephen F Smagula; Helmet T Karim; Eric J Lenze; Meryl A Butters; Gregory F Wu; Benoit H Mulsant; Charles F Reynolds; Howard J Aizenstein Journal: Int J Geriatr Psychiatry Date: 2016-09-19 Impact factor: 3.485
Authors: K Droppa; H T Karim; D L Tudorascu; J F Karp; C F Reynolds; H J Aizenstein; M A Butters Journal: J Psychiatr Res Date: 2017-08-08 Impact factor: 4.791
Authors: Ellen E Lee; Suzi Hong; Averria Sirkin Martin; Lisa T Eyler; Dilip V Jeste Journal: Am J Geriatr Psychiatry Date: 2016-10-17 Impact factor: 4.105
Authors: M Morrens; C Overloop; V Coppens; E Loots; M Van Den Noortgate; S Vandenameele; M Leboyer; L De Picker Journal: Mol Psychiatry Date: 2022-04-28 Impact factor: 15.992
Authors: Cutter A Lindbergh; Kaitlin B Casaletto; Adam M Staffaroni; Fanny Elahi; Samantha M Walters; Michelle You; John Neuhaus; Will Rivera Contreras; Paul Wang; Anna Karydas; Jesse Brown; Amy Wolf; Howie Rosen; Yann Cobigo; Joel H Kramer Journal: J Gerontol A Biol Sci Med Sci Date: 2020-07-13 Impact factor: 6.053
Authors: Carmen Andreescu; Olusola Ajilore; Howard J Aizenstein; Kimberly Albert; Meryl A Butters; Bennett A Landman; Helmet T Karim; Robert Krafty; Warren D Taylor Journal: Am J Geriatr Psychiatry Date: 2019-08-07 Impact factor: 4.105
Authors: C E Millett; J Harder; J J Locascio; M Shanahan; G Santone; R N Fichorova; A Corrigan; C Baecher-Allan; K E Burdick Journal: Brain Behav Immun Date: 2020-04-06 Impact factor: 7.217
Authors: Sarah T Stahl; Stephen F Smagula; Juleen Rodakowski; Mary Amanda Dew; Jordan F Karp; Steven M Albert; Meryl Butters; Ariel Gildengers; Charles F Reynolds Journal: Am J Geriatr Psychiatry Date: 2020-06-25 Impact factor: 4.105
Authors: Natalie M Zahr; Kilian M Pohl; Allison J Kwong; Edith V Sullivan; Adolf Pfefferbaum Journal: Int J Mol Sci Date: 2021-05-07 Impact factor: 6.208